Paediatric Intensive Care Unit, Apollo Children's Hospital, Chennai, India.
Centre for International Child Health, Vancouver, BC, Canada.
Lancet Child Adolesc Health. 2023 Aug;7(8):588-598. doi: 10.1016/S2352-4642(23)00103-7. Epub 2023 Jun 21.
Septic shock is a leading cause of hospitalisation, morbidity, and mortality for children worldwide. In 2020, the paediatric Surviving Sepsis Campaign (SSC) issued evidence-based recommendations for clinicians caring for children with septic shock and sepsis-associated organ dysfunction based on the evidence available at the time. There are now more trials from multiple settings, including low-income and middle-income countries (LMICs), addressing optimal fluid choice and amount, selection and timing of vasoactive infusions, and optimal monitoring and therapeutic endpoints. In response to developments in adult critical care to trial personalised haemodynamic management algorithms, it is timely to critically reassess the current state of applying SSC guidelines in LMIC settings. In this Viewpoint, we briefly outline the challenges to improve sepsis care in LMICs and then discuss three key concepts that are relevant to management of children with septic shock around the world, especially in LMICs. These concepts include uncertainties surrounding the early recognition of paediatric septic shock, choices for initial haemodynamic support, and titration of ongoing resuscitation to therapeutic endpoints. Specifically, given the evolving understanding of clinical phenotypes, we focus on the controversies surrounding the concepts of early fluid resuscitation and vasoactive agent use, including insights gained from experience in LMICs and high-income countries. We outline the key components of sepsis management that are both globally relevant and translatable to low-resource settings, with a view to open the conversation to the large variety of treatment pathways, especially in LMICs. We emphasise the role of simple and easily available monitoring tools to apply the SSC guidelines and to tailor individualised support to the patient's cardiovascular physiology.
脓毒性休克是全球导致儿童住院、发病和死亡的主要原因。2020 年,儿科脓毒症存活运动(SSC)根据当时的现有证据,为治疗脓毒性休克和与脓毒症相关的器官功能障碍的患儿的临床医生发布了循证推荐。现在有更多来自多个环境(包括低收入和中等收入国家(LMIC))的试验,针对最佳液体选择和用量、血管活性输注的选择和时机,以及最佳监测和治疗终点,提出了优化方案。鉴于成人重症监护领域的发展,试验个性化血流动力学管理算法,及时对在 LMIC 环境中应用 SSC 指南的现状进行批判性重新评估是适时的。在本观点中,我们简要概述了改善 LMIC 中脓毒症治疗的挑战,然后讨论了与全球,特别是 LMIC 中脓毒性休克患儿管理相关的三个关键概念。这些概念包括对儿科脓毒性休克早期识别的不确定性、初始血流动力学支持的选择以及对持续复苏至治疗终点的滴定。具体来说,鉴于对临床表型的不断深入了解,我们重点关注早期液体复苏和血管活性药物使用概念的争议,包括从 LMIC 和高收入国家的经验中获得的见解。我们概述了脓毒症管理的关键组成部分,这些组成部分在全球范围内具有相关性,并且可以转化为低资源环境,旨在为各种治疗途径,特别是在 LMIC 中展开讨论。我们强调了简单且易于获得的监测工具的作用,以应用 SSC 指南并根据患者的心血管生理学为其提供个性化支持。